This article discusses the use of dupilumab, a monoclonal antibody, in the treatment of eosinophilic esophagitis (EoE). The study aimed to determine if dupilumab could improve the clinical and histologic features of EoE before 12 weeks of treatment. The researchers conducted a retrospective study on 79 patients and found that dupilumab induced histologic remission and clinical benefit even before 12 weeks of treatment. There were no significant differences in outcomes between patients on dupilumab for different durations. Further research is needed to determine the appropriate timing for repeat evaluations. [Extracted from the article]